The clinical impact of switching attention deficit hyperactivity disorder patients from OROS®-MPH to Novo-MPH ER-C®: A paediatric practice review | Zendy

Judy PM van Stralen | Zendy

Open Access

The clinical impact of switching attention deficit hyperactivity disorder patients from OROS®-MPH to Novo-MPH ER-C®: A paediatric practice review

Author(s) -

Judy PM van Stralen

Publication year - 2013

Publication title -

paediatrics and child health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.55

H-Index - 43

eISSN - 1918-1485

pISSN - 1205-7088

DOI - 10.1093/pch/18.2.70

Subject(s) - attention deficit hyperactivity disorder , medicine , psychiatry , pediatrics , psychology

In Canada, novo-methylphenidate extended-release capsules (Novo-MPH ER-C, Novopharm Limited, Canada) was approved as being bioequivalent to a current first-line treatment for attention deficit hyperactivity disorder (ADHD), CONCERTA (OROS-MPH, Janssen Inc, Canada). The present practice review was undertaken to determine whether bioequivalence of these products translates into therapeutic equivalence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research